Corbus (CRBP) CEO Yuval Cohen sells shares in Rule 10b5-1 tax-cover transaction

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported an open-market sale of 13,871 shares of common stock at a weighted average price of $7.7826 per share on February 13, 2026.

According to the disclosure, this sale was executed under a Rule 10b5-1 trading plan adopted on March 14, 2025 and was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units (RSUs), rather than a discretionary trade. Following this transaction, Cohen directly owned 174,316 shares, which includes 138,049 unvested RSUs subject to their existing vesting schedules.

Insights

Equity compensation and governance analyst

CEO sale is routine tax withholding under a preset plan.

The CEO of Corbus Pharmaceuticals Holdings, Inc., Yuval Cohen, sold 13,871 common shares at a weighted average of $7.7826 per share on February 13, 2026. The filing states the transaction was an open-market sale.

A key detail is that the sale was executed under a Rule 10b5-1 trading plan adopted on March 14, 2025 and is described as a mandatory “sell to cover” for tax withholding on RSU vesting. The text explicitly notes this does not represent a discretionary trade by the reporting person.

After the sale, Cohen’s direct holdings totaled 174,316 shares, including 138,049 unvested RSUs subject to their vesting schedules. This indicates continued significant equity exposure, and the transaction reads as routine equity-compensation housekeeping rather than a thesis-changing move.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Yuval

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	02/13/2026		S(1)		13,871	D	$7.7826(2)	174,316(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/ Yuval Cohen	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corbus Pharmaceuticals (CRBP) report on this Form 4?

Corbus Pharmaceuticals reported that CEO and director Yuval Cohen sold 13,871 shares of common stock. The shares were sold at a weighted average price of $7.7826 per share in an open-market transaction dated February 13, 2026, according to the Form 4 filing.

Why did Corbus Pharmaceuticals (CRBP) CEO Yuval Cohen sell 13,871 shares?

The Form 4 states the sale was to cover tax withholding obligations from vesting and settlement of RSUs. It was executed under a Rule 10b5-1 trading plan and described as a mandatory “sell to cover” transaction, not a discretionary trade by the CEO.

Was the Corbus Pharmaceuticals (CRBP) CEO’s stock sale discretionary?

No, the filing explains the sale does not represent a discretionary transaction. It was mandated by the company’s election to satisfy tax withholding through a “sell to cover” under a pre-established Rule 10b5-1 trading plan adopted on March 14, 2025.

How many Corbus Pharmaceuticals (CRBP) shares does CEO Yuval Cohen hold after this sale?

After selling 13,871 shares, Yuval Cohen directly held 174,316 shares of Corbus Pharmaceuticals common stock. The footnotes clarify that this total includes 138,049 unvested RSUs, which remain subject to each grant’s existing vesting schedule as previously reported.

What price range were Corbus Pharmaceuticals (CRBP) shares sold at in this Form 4?

The reported weighted average sale price was $7.7826 per share. Footnote disclosure adds that multiple trades occurred within a range from $7.58 to $7.96 per share, and detailed breakdowns are available upon request from the reporting person.

What is the significance of the Rule 10b5-1 plan mentioned for Corbus (CRBP)?

The Form 4 notes the transaction was executed under a Rule 10b5-1 trading plan adopted on March 14, 2025. Such plans pre-schedule trades, allowing insiders to sell shares automatically, which can reduce concerns about timing trades around material nonpublic information disclosures.